CRNX News & Events

Crinetics Pharmaceuticals presented data from the open-label, Phase 2 congenital adrenal hyperplasia adult study of investigational atumelnant, a novel, once-daily oral adrenocorticotropic hormone receptor antagonist candidate being developed for the treatment of classic CAH and ACTH-dependent Cushing's syndrome. The findings were included in an oral presentation titled "Once Daily Atumelnant Enables Lowering of Glucocorticoid Doses with Sustained Androgen Reduction in Adults with Congenital Adrenal Hyperplasia" at Endocrine Society's Annual Meeting, ENDO 2026.

Crinetics Pharmaceuticals announced new long-term data from its clinical development program evaluating novel Palsonify in acromegaly during an oral presentation at the Endocrine Society's Annual Meeting, ENDO 2026. Notably, pooled data from the open-label extension, OLE, trials of Pathfndr-1 and Pathfndr-2 show that after two years of treatment, Palsonify was effective and well-tolerated in patients who were switched from standard-of-care monthly injectable somatostatin receptor ligands and those who were medically untreated, respectively, when oral, once-daily Palsonify was initiated.